44 Participants Needed

Robotic Walking Device for Child Movement Disorders

MJ
TC
TC
Overseen ByThomas C Bulea, Ph.D.
Age: < 18
Sex: Any
Trial Phase: Academic
Sponsor: National Institutes of Health Clinical Center (CC)
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 3 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores whether a robotic device worn on the legs can improve walking in children with certain movement disorders. The device, called an exoskeleton, offers a new method to train walking for children with conditions such as cerebral palsy, spina bifida, muscular dystrophy, or spinal cord injuries. Participants will use the device, known as EA-KAFO, in various settings to observe changes in their walking. Children aged 3 to 17 who have difficulty walking due to knee joint issues may be suitable for this study. As an unphased trial, this study provides a unique opportunity for children to potentially enhance their mobility with innovative technology.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that this robotic walking device is safe for children with movement disorders?

Research shows that robotic exoskeletons, like the one tested in this study, are safe and effective for children with movement problems. These devices aim to improve mobility, and past studies have demonstrated their effectiveness. Although specific results from this study are not yet available, similar devices have shown positive outcomes without major safety concerns. This suggests they could benefit children with conditions such as cerebral palsy, spina bifida, and muscular dystrophy.12345

Why are researchers excited about this trial?

Researchers are excited about the EA-KAFO treatment for child movement disorders because it involves a cutting-edge robotic walking device. Unlike traditional methods like physical therapy and standard orthotic devices that mainly focus on passive support, this device actively assists in walking. Its innovative design aims to improve mobility and independence by providing dynamic movement support, potentially leading to better outcomes and faster progress for children. This approach represents a significant leap forward in how we can help children with movement challenges.

What evidence suggests that this robotic device is effective for improving walking ability in children with gait disorders?

This trial will evaluate the effectiveness of a robotic walking device, EA-KAFO, for children with movement disorders. Studies have shown that robotic exoskeletons can improve walking in children with conditions like cerebral palsy and spinal cord injury. Research indicates that these devices can strengthen muscles and help children walk faster and more steadily. Specifically, one study found that children using the robotic device could straighten their knees better, aiding in standing up straighter while walking. Initial findings also suggest the device can help children take bigger steps. These improvements can ease daily activities and enhance overall mobility. Participants in this trial will be divided into two groups: Group A will receive the 12-week study intervention with the EA-KAFO device, while Group B will serve as a control group for the first 12 weeks.13456

Who Is on the Research Team?

TC

Thomas C Bulea, Ph.D.

Principal Investigator

National Institutes of Health Clinical Center (CC)

Are You a Good Fit for This Trial?

Children aged 3-17 with knee-related gait disorders from cerebral palsy, muscular dystrophy, spina bifida, or incomplete spinal cord injury. They must be able to walk at least 10 feet and commit to the study's duration. Pregnant individuals or those with other conditions affecting walking ability are excluded.

Inclusion Criteria

Stated willingness to comply with all study procedures and availability for the duration of the study, or alternatively, ability to do so based on parent report and physician observation during history and physical examination.
I am between 3 and 17 years old.
Provision of signed and dated separate informed consent and assent forms for screening purposes. Upon inclusion in the protocol, provision of signed and dated informed consent and assent forms to begin participation in the study will be necessary.
See 5 more

Exclusion Criteria

I have no health issues affecting my walking except for cerebral palsy, muscular dystrophy, spina bifida, or incomplete spinal cord injury.
I have not had uncontrolled seizures in the last year.
Pregnancy. A urine test will be performed for all participants who are able to become pregnant at the initial screening visit and in the case of a positive test, the participant will be excluded from participation. Further monitoring will rely on self-reporting of interruption in menstruation that would require re-testing for pregnancy at the next visit.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

In-lab Training and Accommodation

Participants undergo in-lab training and accommodation with the exoskeleton to ensure proper fit and operation

12 weeks
Multiple visits (in-person)

Exoskeleton Intervention

Participants use the exoskeleton at home for 1 hour per day, 5 days per week

12 weeks
Home-based

Standard Therapy

Participants continue with their standard therapy regimen

12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 weeks
2 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • EA-KAFO
Trial Overview The trial tests a pediatric robotic exoskeleton (P.REX/Agilik) designed for children with movement disorders. It involves three phases: standard therapy continuation, lab-based exoskeleton training with customized fitting, and home use of the device for walking practice.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Group AExperimental Treatment1 Intervention
Group II: Group BActive Control1 Intervention

EA-KAFO is already approved in United States, Canada for the following indications:

🇺🇸
Approved in United States as Agilik for:
🇨🇦
Approved in Canada as Agilik for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

National Institutes of Health Clinical Center (CC)

Lead Sponsor

Trials
391
Recruited
30,880,000+

Published Research Related to This Trial

The multi-robot system designed to assist children with developmental delays in learning to walk includes a pelvic module and a hip module, providing customizable support for gait with high precision in motion tracking (2 mm RMS error for the pelvic module and <0.1 mm RMS error for the hip module).
Both modules can operate independently or together, allowing for flexible configurations that adapt to the specific needs of each child, making the system highly effective for personalized gait assistance.
Design and preliminary evaluation of a multi-robotic system with pelvic and hip assistance for pediatric gait rehabilitation.Park, EJ., Kang, J., Su, H., et al.[2018]
The study demonstrated that using a walker device combined with microswitches and preferred stimuli effectively increased locomotion in two children with severe disabilities, showing positive results in their step responses during the intervention phases.
This research replicates previous pilot studies, reinforcing the idea that such interventions can motivate children with disabilities to engage in more movement, which is crucial for their development and social interaction.
Promoting step responses of children with multiple disabilities through a walker device and microswitches with contingent stimuli.Lancioni, GE., De Pace, C., Singh, NN., et al.[2018]
In a study of 89 children and adolescents undergoing robotic-assisted treadmill therapy, 42.7% experienced mild adverse events, primarily skin irritation and muscle pain, but no severe side effects were reported.
The therapy was deemed safe overall, allowing for extended gait training periods despite some patients experiencing minor issues that occasionally limited their treatment.
Safety of robotic-assisted treadmill therapy in children and adolescents with gait impairment: a bi-centre survey.Borggraefe, I., Klaiber, M., Schuler, T., et al.[2010]

Citations

A randomized cross-over study protocol to evaluate long ...A study of ambulatory children with bilateral cerebral palsy found decreased volition in motor control and muscle activation of the legs when ...
Evaluating Long-term Use of a Pediatric Robotic ...This randomized crossover trial will determine whether 12 weeks of overground gait training with a robotic exoskeleton outside of the clinical ...
Evaluating a pediatric exoskeleton to improve ... - NIH RePORTERThe primary outcome measure is peak knee extension during midstance during walking, with secondary outcome measures including gait speed, step length, knee ...
Robotic Walking Device for Child Movement DisordersThis trial tests a robotic exoskeleton that helps children with walking difficulties due to conditions like cerebral palsy or spinal cord injury.
Researcher View | NCT05726591 | Evaluating Long-term ...To evaluate changes in muscle strength and gait speed following longitudinal intervention with robotic exoskeleton in children with crouch gait from CP or knee ...
Project Details - NIH RePORTERThe aim of the study is to investigate the safety and effectiveness of a robotic exoskeleton for overground gait training targeting improvements to knee angle ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security